IBM's Watson Genomics is being added to Illumina's TruSight Tumor 170, a tool that matches cancer patients with drugs that might help them. Steve Harvey, vice president of Watson Health, said that some two million Americans would benefit from having their tumour DNA sequenced, but fewer than 10% do. The aim of the partnership is to make it easier for hospitals to get started with DNA sequencing. What the new product offers a hospital pathologist is a way to buy an extra machine to run an extra test, without farming it out to a service outside the hospital. Illumina has also been working on its own version of Watson, called Watson.
IBM's Watson Genomics is being added to Illumina's TruSight Tumor 170, a tool that matches cancer patients with drugs that might help them. Steve Harvey, vice president of Watson Health, said that some two million Americans would benefit from having their tumour DNA sequenced, but fewer than 10% do. The aim of the partnership is to make it easier for hospitals to get started with DNA sequencing. Illumina has also been working on its own version of Watson, called Watson.